GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mainz Biomed NV (NAS:MYNZ) » Definitions » Dividend-Payout-to-FFO

MYNZ (Mainz Biomed NV) Dividend-Payout-to-FFO


View and export this data going back to 2021. Start your Free Trial

What is Mainz Biomed NV Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.


Mainz Biomed NV Business Description

Traded in Other Exchanges
N/A
Address
Robert Koch Strasse 50, Sirius Gutenberg Park, Mainz, RP, DEU, 55129
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.